Can CRISPR editing of NRF2 reverse resistance in head and neck squamous cell carcinoma?
CorriXR’s new data show CRISPR-based NRF2 disruption restores chemo response in squamous tumors. Find out what this could mean for HNSCC treatment.
Pharma & Biotech
Pharma & Biotech
Brazil rollout puts Bavarian Nordic’s chikungunya vaccine under regulatory and execution scrutiny
Find out how Bavarian Nordic’s Brazil rollout with Eurofarma puts its chikungunya vaccine to the ultimate regulatory and execution test.
Pharma & Biotech
Vaxcyte advances VAX-31 as Phase 3 trial design choices highlight regulatory and adoption priorities
Vaxcyte advances VAX-31 into pivotal adult and infant studies. Find out how trial design choices shape regulatory and adoption outcomes.
Pharma & Biotech
How amlitelimab’s dosing flexibility could disrupt biologic treatment patterns in atopic dermatitis
Sanofi’s amlitelimab advances toward filing in atopic dermatitis. Explore how dosing flexibility, durability data, and regional results shape its outlook.
Pharma & Biotech
How PDS0101 patent coverage reshapes competitive risk in HPV16 positive head and neck cancer development
PDS Biotechnology strengthens PDS0101 patent protection as Phase 3 strategy evolves. Discover what this changes for immunotherapy competition.
Pharma & Biotech
INTENT Biologics secures FDA pediatric waiver, clears path to late-stage DFU trial for PEP Biologic
The U.S. Food and Drug Administration (FDA) has granted INTENT Biologics a full pediatric study waiver for its lead candidate, PEP Biologic, under IND 019567. The waiver, part of an agreed Initial Pediatric Study Plan (iPSP), applies to the product’s adult-focused development for diabetic foot ulcers (DFUs), a serious chronic wound indication preparing for pivotal
Pharma & Biotech
Insilico, Hygtia Therapeutics to co-develop brain-penetrant NLRP3 inhibitor ISM8969 for CNS diseases
Clinical-stage biotechnology company Insilico Medicine (HKEX: 3696) and Hygtia Therapeutics, a Shenzhen Pengfu Fund–backed startup under Fosun Health Capital, have entered into an exclusive co-development and licensing agreement to jointly advance ISM8969, a novel brain-penetrant NLRP3 inhibitor for central nervous system diseases. The deal grants 50-50 worldwide rights to both companies, with Insilico eligible to
Pharma & Biotech
Adaptin Bio prepares Phase 1 glioblastoma trial following preclinical progress in brain cancer candidate
Find out how Adaptin Bio is preparing a Phase 1 glioblastoma trial and why its preclinical progress matters for brain cancer treatment innovation.
Pharma & Biotech
MAIA Biotechnology advances ateganosine cancer program with Phase 3 THIO-104 trial and 2026 catalyst timeline
Find out how MAIA Biotechnology is advancing ateganosine into Phase 3 and why its 2026 clinical milestones could reshape treatment options in lung cancer.
Pharma & Biotech
Lilly’s sofetabart mipitecan gets FDA Breakthrough Therapy designation for ovarian cancer
Eli Lilly and Company has received Breakthrough Therapy designation from the U.S. Food and Drug Administration for its investigational antibody-drug conjugate, sofetabart mipitecan, also known as LY4170156. The designation applies to adult patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received prior treatment with bevacizumab and mirvetuximab soravtansine. The novel